The rising costs of drug development, coupled with increasing regulatory pressures, have driven life sciences organizations to reimagine the way clinical trials are conducted – the focus is increasingly shifting toward failing fast and cheap. However, challenges such as siloed data management, delayed timelines due to patient recruitment concerns, and a complex environment of multiple technology solutions aggravate a pharma organization’s woes further. Digital technologies and products have been deployed across the clinical trial landscape to resolve these challenges and bring in efficiencies and automation to reduce manual errors.
Recently, product vendors have started integrating siloed point solutions into an integrated, modular, and interoperable end-to-end clinical development platform – a single platform to address a pharma organization’s needs, right from study start-up to study closeout. A single-platform estate enables efficient data management, reduces the total cost of ownership, and improves the visibility of operations. However, pharma executives are yet to be convinced about a unified platform approach.
In this research, we present a deep dive into the size of the clinical trial products market, Everest Group’s view of a unified clinical development platform landscape, enterprise views around unified clinical development platforms, and the challenges to adopting such platforms.
Scope
Geography: global
Industry: life sciences – biopharma, medical devices, and Contract Research Organizations (CROs)
Vendor offering: clinical development platforms
Contents
This report looks at:
- Clinical trial products’ market size
- Everest Group view of a unified clinical development platform landscape
- Enterprise view of unified clinical development platforms and challenges to adopting such platforms
Membership(s)
Life Sciences IT Services (ITS)
Sourcing and Vendor Management
